Abbott Laboratories (NYSE:ABT) has been rated by 11 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $50 and the lowest price target forecast is $45. The average forecast of all the analysts is $47.55 and the expected standard deviation is $1.75.
Abbott Laboratories has lost 0.81% in the last five trading days and dropped 0.48% in the last 4 weeks. Abbott Laboratories has dropped 6.26% during the last 3-month period . Year-to-Date the stock performance stands at -11.38%. Also, Equity Analysts at the Edward Jones upgrades the rating on Abbott Laboratories (NYSE:ABT). The brokerage firm has issued a Buy rating on the shares. The shares were previously rated Hold. The rating by the firm was issued on June 21, 2016.
Abbott Laboratories (NYSE:ABT) : 16 analysts are covering Abbott Laboratories (NYSE:ABT) and their average rating on the stock is 1.63, which is read as a Buy. 10 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Abbott Laboratories (NYSE:ABT) also receives 2 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Abbott Laboratories (NYSE:ABT): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $38.65 and $38.57 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $39.31. The buying momentum continued till the end and the stock did not give up its gains. It closed at $39.31, notching a gain of 1.92% for the day. The total traded volume was 10,425,042 . The stock had closed at $38.57 on the previous day.
In an insider trading activity,The officer (Senior Vice President) of Abbott Laboratories, Watkin Jared sold 552 shares at $37.63 on June 15, 2016. The Insider selling transaction had a total value worth of $20,772. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.